Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds
SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “abiraterone-like” agent in comparison with placebo — though radiographic progression-free survival was improved. …
